Loading financials from SEC filings…
Drug manufacturers · Healthcare · Fiscal year ends Dec 31
Net income was −$125M. Operating cash flow of −$95M less capital expenditure of $128,000 left free cash flow of −$96M.
Last 5 fiscal years
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Research & development | 73.9 | 112 | 104 | 115 | 92.9 |
| Operating income | −125 | −247 | −142 | −180 | −141 |
| Pre-tax income | – | – | – | −162 | −125 |
| Income tax | – | – | – | 0.0 | 0.0 |
| Net income | −123 | −243 | −125 | −162 | −125 |
| Diluted EPS | −1.85 | −1.99 | −0.83 | −0.69 | −0.44 |
| Diluted shares | 66.3 | 122 | 150 | 234 | 284 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | 360 | 284 | 93.1 | 67.7 | 73.8 |
| Current assets | 420 | 444 | 321 | 309 | 286 |
| Net PP&E | 16.0 | 24.8 | 22.3 | 16.3 | 13.3 |
| Total assets | 501 | 515 | 395 | 503 | 396 |
| Payables | 4.7 | 23.0 | 2.0 | 0.5 | 1.0 |
| Current liabilities | 26.2 | 48.7 | 26.2 | 31.4 | 28.5 |
| Total liabilities | 44.9 | 103 | 78.6 | 79.0 | 71.0 |
| Shareholders' equity | 457 | 412 | 317 | 423 | 325 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating cash flow | −79.6 | −103 | −101 | −109 | −95.5 |
| Capital expenditure | 11.2 | 14.6 | 1.8 | 0.1 | 0.1 |
| Free cash flow | −90.8 | −118 | −103 | −109 | −95.6 |
| Depreciation & amortisation | 0.8 | 2.6 | 3.7 | 3.8 | 3.1 |
| Stock-based compensation | 8.3 | 20.1 | 26.2 | 27.0 | 24.9 |
| Dividend per share | – | 0.00 | 0.00 | 0.00 | 0.00 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Return on equityBlank when equity is negative | −26.9% | −59.0% | −39.5% | −38.2% | −38.3% |
| ROCEEBIT ÷ (assets − current liabilities) | −26.3% | −53.1% | −38.3% | −38.1% | −38.3% |
| Cash conversion (CFO ÷ net income) | 0.65x | 0.43x | 0.81x | 0.68x | 0.77x |
| Current ratio | 16.0x | 9.13x | 12.3x | 9.84x | 10.0x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.